Company / Gross Margin
RIGEL PHARMACEUTICALS INC Gross Margin History
FY2018-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Margin
13.4%
FY2019
5-year range
-
FY2018-FY2019
Trend
+55.5%
vs FY2018
Sector context
#29 of 28
Health Care
What the data says
Among 28 Health Care companies, RIGEL PHARMACEUTICALS INC is in the bottom -4% for gross margin.
Based on SEC 10-K filings.
13.4% in FY2019.
Health Care sector context is included.
Gross Margin over time
Growth rates
- 3-Year Change
- -
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
Bottom -4% in Health CareTop 104% of 28This company 13.4% Sector average 60.3%
▼
-77.8% below sector average
Key checks
Key Insights
- In FY2019, gross margin increased 55.5% year-over-year.
- Currently 46.9pp below the Health Care sector average.
Company context
Key Data Points
- Altman Z-Score 1.19 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | 13.4% | +55.5% |
| FY2018 | 8.6% | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2019 · SEC 10-K · Updated Jun 30, 2026